Cincinnati, OHNCT07173803Now EnrollingIRB Ready

Progressive Supranuclear Palsy(PSP) Clinical Trial in Cincinnati, OH

Access cutting-edge progressive supranuclear palsy(psp) treatment through this phase 2 clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.

Sponsored by Adam Boxer

Quick Self-Assessment

See if you qualify for this Cincinnati location

Preparing your pre-screening questions…

Expert Care in Cincinnati

Access progressive supranuclear palsy(psp) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related progressive supranuclear palsy(psp) treatment provided free

Apply for This Cincinnati Location

Check if you qualify for this progressive supranuclear palsy(psp) clinical trial in Cincinnati, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cincinnati

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cincinnati site if eligible
  4. 4Begin participation

About This Progressive Supranuclear Palsy(PSP) Study in Cincinnati

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.

Sponsor: Adam Boxer

Who Can Participate

Inclusion Criteria

Clinical diagnosis of possible or probable PSP Richardson's Syndrome as defined by the 2017 Movement Disorder Society (MDS) criteria.
Presence of PSP symptoms for ≤5 years at screening (based on the best judgment of the site PI).
Mini-Mental State Examination (MMSE) score at screening of ≥25.
Able to walk at least 10 steps with minimal assistance (e.g., one arm for safety, but not postural support).
Stable doses of permitted medications as described per protocol for 30 days prior to screening.
Resides at home or in the community (assisted living is acceptable).
As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.

Exclusion Criteria

Females who are breastfeeding or pregnant (as documented by a urine pregnancy test) during screening, or plan to become pregnant during the study.
Females of childbearing potential who did not use a highly effective method of contraception within 28 days of screening and/or are not willing to use a highly effective method of contraception for the duration of their participation in the study.
Lacks good venous access such that multiple blood draws would be precluded.
Weighs less than 40kg, or more than 136kg at screening.
Blood transfusion within 4 weeks of screening.
Contraindications to MRI studies, including metal (ferromagnetic) implants, a cardiac pacemaker that is not compatible with MRI, and/or severe claustrophobia.
Screening MRI scan showing structural evidence of alternative pathology not consistent with PSP that could explain a substantial portion of the participant's symptoms as indicated by the central MRI read.
Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular or cardiovascular conditions), as per the site PI's judgment.
History of severe allergic reaction (e.g., anaphylaxis) including but not limited to: severe allergic reaction to previous vaccines, foods, and/or medications.
Hospitalization within 30 days prior to screening or baseline.
Infections or major surgical procedures within 3 months prior to screening, judged to be clinically significant by the site PI.
Myocardial infarction within 1 year prior to baseline, unstable angina pectoris, symptomatic congestive heart failure.
History of cancer within the past 5 years other than treated skin squamous cell carcinoma, basal cell carcinoma, and melanoma in-situ, localized prostate cancer not requiring treatment, or prostate or breast cancer, which have been fully removed and are considered cured.
History or presence of immunological or inflammatory conditions, including neurological disorders, meningitis or meningoencephalitis.
History or presence of epilepsy requiring ongoing use of antiepileptic medications. Antiepileptic medications are permitted for pain or psychiatric use per the protocol.
DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.
Clinically significant abnormal vital signs including sustained sitting blood pressure \>160/100 mm Hg.
Diabetes mellitus with hemoglobin A1c (HbA1c) levels of ≥8.0%.
Known history of human immunodeficiency virus (HIV-1 or 2).
Known history of acute/chronic hepatitis B or C unless treated curatively.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cincinnati?

Yes, this clinical trial (NCT07173803) has an active research site in Cincinnati, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Progressive Supranuclear Palsy(PSP) Treatment Options in Cincinnati, OH

If you're searching for progressive supranuclear palsy(psp) treatment options in Cincinnati, OH, this clinical trial (NCT07173803) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cincinnati research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced progressive supranuclear palsy(psp) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all progressive supranuclear palsy(psp) clinical trials near you to find additional studies recruiting in your area.

More ALS Trials in Cincinnati, OH

See all als clinical trials recruiting in Cincinnati — not just this study.

Browse ALS Trials in Cincinnati →

Browse More Trials by Condition

ALS TrialsRheumatoid Arthritis TrialsUlcerative Colitis TrialsAll Conditions →

Ready to Join in Cincinnati?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cincinnati, OH